UBS Knock-Out AMGN/ DE000UL6VAD7 /
2024-05-14 1:53:34 PM | Chg.-0.010 | Bid3:42:01 PM | Ask3:42:01 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
0.470EUR | -2.08% | 0.490 Bid Size: 250,000 |
0.510 Ask Size: 250,000 |
Amgen Inc | 256.3458 USD | 2078-12-31 | Call |
GlobeNewswire
3:00 PM
Accumulus Synergy Sponsors Revolutionary Healthcare Data Standard, Advancing Towards Global Dossier
GlobeNewswire
1:30 PM
Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024
GlobeNewswire
9:00 AM
Nouscom Appoints Leading Cancer Drug Development Expert, Neil Gallagher, MD, PhD, as Independent Adv...
GlobeNewswire
05-13
TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
05-09
argenx Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
05-08
CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 ...
GlobeNewswire
05-08
CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
05-08
Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination ...
GlobeNewswire
05-07
CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination wi...
GlobeNewswire
05-02
Unleashing the Power of MAIT Cells: Pluri Launches Novel Immunotherapy Platform for Solid Tumor Canc...
GlobeNewswire
05-01
Fight Colorectal Cancer Launches ChatCRC: An AI-Powered Chatbot Revolutionizing Colorectal Cancer Su...
GlobeNewswire
05-01
CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clin...
GlobeNewswire
04-30
Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab bios...